Argomenti trattati
The Philadelphia life sciences community reconvenes on April 25, 2026 for the second annual Wharton Biotech Conference, hosted at Jon M. Huntsman Hall. Organized by the student-run Penn Biotech Group (PBG) as it marks its 25th year of service, the event promises a full day of panels, workshops, and networking designed for people building careers across the biotech landscape. The conference gathers a wide cross-section of participants — from laboratory investigators to early-stage investors — and emphasizes the region’s dense mix of academic research, startup energy, and industrial know-how.
Penn Biotech Group is the University of Pennsylvania’s largest healthcare consulting club, with more than 300 active members representing nine of Penn’s 12 graduate schools. For a quarter-century, PBG has offered pro-bono consulting to biotech and pharmaceutical organizations while creating hands-on pathways into venture capital and entrepreneurship. The conference doubles as a community hub to reinforce collaborations, spotlight translational projects, and introduce emerging professionals to local ecosystem players.
Program and tracks
The conference program is structured into two concurrent tracks so attendees can customize their day around specific interests. Sessions mix presentations, moderated panels, and Q&A to address scientific developments, commercialization strategies, and workforce issues. More than 40 speakers across sectors and career stages will contribute perspectives on everything from early-stage discovery to market entry and regulatory pathways. Themes include the commercialization lifecycle, investor decision-making, and the accelerating role of artificial intelligence in biomedical research.
Track A: innovation, science & capital
Track A focuses on how discoveries transition from bench to company, highlighting the mechanics of translational science and funding models that support that journey. Panels will examine partnerships between academic labs and industry, metrics investors use to evaluate biotech opportunities, and the operational hurdles of scaling technologies. A recurring thread is the expanding use of artificial intelligence to accelerate target identification, optimize preclinical workflows, and streamline aspects of clinical development and commercialization.
Track B: policy, commercialization & careers
Track B spotlights the external environment that shapes biotech success: policy, regulation, reimbursement, and market-entry strategy. Sessions are designed to give both established professionals and newcomers actionable guidance about navigating regulatory interactions and building commercially viable products. Career-focused conversations will explore role trajectories across startups, health systems, investor firms, and corporate strategy teams, offering practical advice for career transitions in the life sciences.
Keynote and leadership
The conference keynote will be delivered by Tiffany Wilson, President & CEO of the University City Science Center. Ms. Wilson has more than two decades of experience converting scientific advances into deployed technologies across medical devices, healthcare technology, and advanced industries. Since her appointment in October 2026, she has guided the Science Center through a strategic transformation toward a venture-aligned innovation intermediary focused on generating new companies, deployed technologies, and quality jobs through evidence-driven commercialization and capital readiness.
Before joining the Science Center, Tiffany Wilson served as CEO of the Global Center for Medical Innovation (GCMI) in Atlanta, where she helped launch and operationalize the organization beginning in 2011. At GCMI she pioneered a capital-efficient model to move medical device concepts through testing, regulatory submission, and market entry. Earlier roles included senior leadership at Scientific Intake and ACell — a regenerative medicine firm later acquired by Integra LifeSciences — and foundational experience in management consulting and investment banking. She holds an MBA from Georgetown University’s McDonough School of Business and a BBA in International Business from Loyola University New Orleans.
Logistics and how to participate
The conference runs from 8 a.m. to 6 p.m. Eastern Time and will include a limited-capacity networking dinner for deeper conversations after the daytime program. Tickets and a detailed agenda will be released ahead of the event; participants are encouraged to preselect sessions in their preferred track and map time for networking. The day is designed to be practical: attendees can expect tangible takeaways about fundraising dynamics, commercialization playbooks, and career pathways in the life sciences.
Who should attend
Recommended attendees include early-career professionals, academic researchers aiming to translate discoveries, investors evaluating regional opportunities, and established industry leaders seeking local partnerships. The conference is also well suited to students and entrepreneurs who want to understand the full lifecycle of biotech innovation, from laboratory insight to market adoption. By convening this community, PBG aims to accelerate collaborations that produce measurable advances in health and industry.
Philadelphia’s biotech ecosystem is positioned for continued growth, and the Wharton Biotech Conference offers a concentrated forum to learn, connect, and contribute. Whether you come to hear about the latest in artificial intelligence, to gain clarity on commercialization strategies, or to expand your professional network, the event seeks to help attendees convert ideas into impact.